Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinflunine as Second-line Treatment for Advanced Non-Small Cell Lung Cancer
NCT00251446Phase 2Completed
- Sponsor
- Veeda Lifesciences
- Start
- Oct 2005
- Primary completion
- Mar 2008
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinflunine in non-small cell lung cancer (NSCLC), sponsored by Veeda Lifesciences. Primary endpoint: 1-year Overall Survival Rate. Started Oct 2005; status: completed.
02
Drugs
vinflunine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00251446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251446.